Vapotherm Inc (Vapotherm) is a medical device company that carries out the development and manufacture of advanced non-invasive respiratory care devices. The company's products portfolio includes precision flow system, HVT 2.0 system, capital accessories, disposable accessories. precision flow system includes precision flow, precision flow heliox, disposable patient circuit. HVT 2.0 system include HVT 2.0, HVT 2.0 disposable. Capital accessories include oxygen assist module, vapotherm transfer unit, Q50 air compressor. Disposable accessories include prosoft nasal cannulas, aerosolized medication, nitric oxide, tracheostomy adapter. It markets its products in the Americas, Europe, Middle East, Asia, Africa and Oceania. Vapotherm is headquartered in Exeter, New Hampshire, the US.
This report is a source for data, analysis, and actionable intelligence on the company’s portfolio of pipeline products. The report provides key information about the company, its major products and brands.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage.
This report is a source for data, analysis, and actionable intelligence on the company’s portfolio of pipeline products. The report provides key information about the company, its major products and brands.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage.
Scope:
- The report reviews detailed company profile with information on business description, key company facts, major products and services, key competitors, key employees, locations and subsidiaries and recent developments
- The report analyzes all pipeline products in development for the company Vapotherm Inc
- The report provides pipeline analysis on all pipeline products of the company (by equipment type, by indication, by development stage, and by trial status)
- The report covers detailed information on each pipeline product with information on pipeline territory, stage of development, device class, regulatory path, indication(s), application(s) and estimated launch date
- The report provides detailed description of products in development, technical specification and functions
- The report also covers ongoing clinical trials (wherever applicable) with information on trial name, trial objective, sponsor, trial design, trial status and phase, estimated start and end date.
Reasons to Buy:
- Develop business strategies by understanding the trends and developments driving the medical devices pipeline and technology landscape
- Design and develop your product development, marketing and sales strategies by understanding the competitor portfolio
- To formulate effective Research & Development strategies
- Develop market-entry and market expansion strategies
- Exploit in-licensing and out-licensing opportunities by identifying products, most likely to ensure a robust return
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop competition strategies by identifying the status and likely launch of the competitors’ pipeline products through review of the clinical trials, stage and of development, etc
- Identify, understand and capitalize the next high-value products that your competitor would add in its portfolio
Table of Contents
- Natera Inc Company Overview
- Natera Inc Company Snapshot
- Natera Inc Pipeline Products and Ongoing Clinical Trials Overview
- Natera Inc - Pipeline Analysis Overview
- Natera Inc - Key Facts
- Natera Inc - Major Products and Services
- Natera Inc Pipeline Products by Development Stage
- Natera Inc Ongoing Clinical Trials by Trial Status
- Natera Inc Pipeline Products Overview
- Fetal Focus 20-gene Test
- Fetal Focus 20-gene Test Product Overview
- Latitude
- Latitude Product Overview
- Non-Invasive Prenatal Screening Test - Preeclampsia
- Non-Invasive Prenatal Screening Test - Preeclampsia Product Overview
- Non-Invasive Prenatal Screening Test - Preeclampsia Clinical Trial
- Panorama Non-Invasive Prenatal Expanded Test
- Panorama Non-Invasive Prenatal Expanded Test Product Overview
- Prospera Pancreas Transplant Rejection Test
- Prospera Pancreas Transplant Rejection Test Product Overview
- Reproductive Health Test
- Reproductive Health Test Product Overview
- Signatera - Anal Squamous Cell Carcinoma
- Signatera - Anal Squamous Cell Carcinoma Product Overview
- Signatera - Breast Cancer
- Signatera - Breast Cancer Product Overview
- Signatera - Breast Cancer Clinical Trial
- Signatera - Colorectal Cancer
- Signatera - Colorectal Cancer Product Overview
- Signatera - Colorectal Cancer Clinical Trial
- Signatera - GI Tumors
- Signatera - GI Tumors Product Overview
- Signatera - GI Tumors Clinical Trial
- Signatera - Lung Cancer (Opdivo)
- Signatera - Lung Cancer (Opdivo) Product Overview
- Signatera - Lung Cancer (Opdivo) Clinical Trial
- Signatera - Metastatic Non-Small Cell Lung Cancer
- Signatera - Metastatic Non-Small Cell Lung Cancer Product Overview
- Signatera - Multiple Myeloma
- Signatera - Multiple Myeloma Product Overview
- Signatera - Non-Hodgkin's Lymphoma
- Signatera - Non-Hodgkin's Lymphoma Product Overview
- Signatera - Ovarian Cancer
- Signatera - Ovarian Cancer Product Overview
- Signatera - Ovarian Cancer Clinical Trial
- Signatera - Pan-Cancer
- Signatera - Pan-Cancer Product Overview
- Signatera - Pancreatic Cancer
- Signatera - Pancreatic Cancer Product Overview
- Signatera - Prostate Cancer
- Signatera - Prostate Cancer Product Overview
- Signatera Companion Diagnostic - Tecentriq
- Signatera Companion Diagnostic - Tecentriq Product Overview
- Natera Inc - Key Competitors
- Natera Inc - Key Employees
- Natera Inc - Locations And Subsidiaries
- Head Office
- Other Locations & Subsidiaries
- Recent Developments
- Natera Inc, Recent Developments
- Jul 22, 2026: Signatera MRD Outperformed AMERK Testing in Predicting Merkel Cell Carcinoma Recurrence in JAMA Dermatology Study
- Jul 16, 2026: Finalized MolDx LCD Includes Expanded Coverage for Natera’s Prospera Portfolio
- Jul 09, 2026: Natera Announces IVDR Certification for Signatera Across Multiple Cancers
- Jul 06, 2026: Natera demonstrates MRD test benefit in colorectal cancer patients
- Jun 25, 2026: Natera and Eledon Announce Strategic Partnership for Prospera Monitoring in Planned Phase 3 Kidney Transplant Trial
- Jun 24, 2026: Signatera Receives Regulatory Approval in Japan for Colorectal Cancer
- Jun 23, 2026: NCCN Recommends ctDNA-MRD Testing Using Signatera Technology in Landmark Bladder Cancer Guideline Update
- Jun 18, 2026: Natera to Showcase Organ Health Leadership With 21 Presentations at the American Transplant Congress
- May 29, 2026: Natera Announces Collaboration With Diakonos Oncology for Signatera in Refractory Melanoma
- May 28, 2026: Natera Enrolls First Patients in SIGNAL-ER 101, a Prospective, Interventional Study Evaluating MRD-Guided Therapy in Breast Cancer
- Appendix
- Methodology
- About the Analyst
- Contact the Publisher
- Disclaimer
- Natera Inc Pipeline Products and Ongoing Clinical Trials Overview
- Natera Inc Pipeline Products by Equipment Type
- Natera Inc Pipeline Products by Indication
- Natera Inc Ongoing Clinical Trials by Trial Status
- Natera Inc, Key Facts
- Natera Inc, Major Products and Services
- Natera Inc Number of Pipeline Products by Development Stage
- Natera Inc Pipeline Products Summary by Development Stage
- Natera Inc Ongoing Clinical Trials by Trial Status
- Natera Inc Ongoing Clinical Trials Summary
- Fetal Focus 20-gene Test - Product Status
- Fetal Focus 20-gene Test - Product Description
- Latitude - Product Status
- Latitude - Product Description
- Non-Invasive Prenatal Screening Test - Preeclampsia - Product Status
- Non-Invasive Prenatal Screening Test - Preeclampsia - Product Description
- Non-Invasive Prenatal Screening Test - Preeclampsia - A Clinical Study to Evaluate the Non-Invasive Prenatal Screening Test for Early Risk Assessment of Preeclampsia and Other Serious Pregnancy Complications
- Panorama Non-Invasive Prenatal Expanded Test - Product Status
- Panorama Non-Invasive Prenatal Expanded Test - Product Description
- Prospera Pancreas Transplant Rejection Test - Product Status
- Prospera Pancreas Transplant Rejection Test - Product Description
- Reproductive Health Test - Product Status
- Reproductive Health Test - Product Description
- Signatera - Anal Squamous Cell Carcinoma - Product Status
- Signatera - Anal Squamous Cell Carcinoma - Product Description
- Signatera - Breast Cancer - Product Status
- Signatera - Breast Cancer - Product Description
- Signatera - Breast Cancer - A Randomized, Phase II Trial of Circulating Tumor DNA-guided Second Line Adjuvant Therapy for High Residual Risk, Estrogen Receptor Positive, HER-2 Negative Breast Cancer (DARE)
- Signatera - Breast Cancer - ABCSG 61 / TEODOR (Neoadjuvant TrEatment Optimization Driven by ctDNA and endOcrine Responsiveness): A Prospective, Randomized, Controlled, Openlabel Multicenter Phase II Study Investigating Neoadjuvant Endocrine Therapy Versus Chemotherapy in HR-positive, HER2negative, ctDNA-negative and Endocrine Responsive Early and Locally Advanced Breast Cancer
- Signatera - Breast Cancer - De-escalation of Medical Therapies in HER2-positive Metastatic Breast Cancer in Long-term Persistent Response and Minimal Residual Disease Undetectable in Circulating Tumor DNA
- Signatera - Breast Cancer - Elacestrant for Treating ER+/HER2- Breast Cancer Patients with ctDNA Relapse
- Signatera - Breast Cancer - HERizon-Breast: A ctDNA-Guided Adaptive Study of Sequential Anti-HER2 Therapies and CNS Prophylaxis to Induce Long-Term Remission
- Signatera - Breast Cancer - Longitudinal ctDNA Monitoring in Older Women With ER+ Breast Cancer Who Forego Upfront Surgery in Favor of Primary Endocrine Therapy
- Signatera - Breast Cancer - Personalized Detection of ctDNA for Patients With HER2-Positive Metastatic Breast Cancer Who Achieved Durable Response by Anti-HER2 Treatment
- Signatera - Breast Cancer - Pre-operative Phase II Trial for Breast Cancer with Nivolumab in Combination with Novel IO (BELLINI Trial)
- Signatera - Breast Cancer - Safe De-escalation of Chemotherapy for Stage 1 Breast Cancer
- Signatera - Breast Cancer - SIgnatera-Guided Initiation of Adjuvant CDK4/6 Inhibitor in Intermediate Risk HR+ HER2- Breast Cancer
- Signatera - Colorectal Cancer - Product Status
- Signatera - Colorectal Cancer - Product Description
- Signatera - Colorectal Cancer - BESPOKE Study of ctDNA Guided Therapy in Colorectal Cancer
- Signatera - Colorectal Cancer - Circulating Tumor DNA Based Decision for Adjuvant Treatment in Colon Cancer Stage II
- Signatera - Colorectal Cancer - Clinical Experience of a Personalized and Tumor-informed Circulating Tumor DNA Assay for Minimal Residual Disease Detection in Oligometastatic Colorectal Cancer Patients
- Signatera - Colorectal Cancer - Colon Adjuvant Chemotherapy Based on Evaluation of Residual Disease
- Signatera - Colorectal Cancer - ctDNA Testing in Resectable Stage II-IV Colorectal Cancer Patients: A Head-to-Head Performance Comparison
- Signatera - Colorectal Cancer - Genetic Alterations and Clinical Record in Radically Resected Colorectal Cancer Revealed by Liquid Biopsy and Whole Exome Analysis
- Signatera - Colorectal Cancer - Tracking Mutations in Cell Free Tumour DNA to Predict Relapse in Early Colorectal Cancer
- Signatera - GI Tumors - Product Status
- Signatera - GI Tumors - Product Description
- Signatera - GI Tumors - Response Adapted Neoadjuvant Therapy in Gastroesophageal Cancers (RANT-GC Trial) - a Phase Ib Feasibility Trial
- Signatera - GI Tumors - SIGNAL GEC-101: Signatera-Guided De-escalation of Adjuvant Therapy in Resectable Stage II-IVa Gastric/Gastric-Esophageal Cancer
- Signatera - Lung Cancer (Opdivo) - Product Status
- Signatera - Lung Cancer (Opdivo) - Product Description
- Signatera - Lung Cancer (Opdivo) - Neoadjuvant Anti-PD-1 Drug Nivolumab Combined with Chemotherapy in the Treatment of Primary Tracheal Squamous Cell Carcinoma
- Signatera - Metastatic Non-Small Cell Lung Cancer - Product Status
- Signatera - Metastatic Non-Small Cell Lung Cancer - Product Description
- Signatera - Multiple Myeloma - Product Status
- Signatera - Multiple Myeloma - Product Description
- Signatera - Non-Hodgkin's Lymphoma - Product Status
- Signatera - Non-Hodgkin's Lymphoma - Product Description
- Signatera - Ovarian Cancer - Product Status
- Signatera - Ovarian Cancer - Product Description
- Signatera - Ovarian Cancer - Investigator-initiated Phase II Study of Pembrolizumab Immunological Response Evaluation
- Signatera - Pan-Cancer - Product Status
- Signatera - Pan-Cancer - Product Description
- Signatera - Pancreatic Cancer - Product Status
- Signatera - Pancreatic Cancer - Product Description
- Signatera - Prostate Cancer - Product Status
- Signatera - Prostate Cancer - Product Description
- Signatera Companion Diagnostic - Tecentriq - Product Status
- Signatera Companion Diagnostic - Tecentriq - Product Description
- Natera Inc, Key Employees
- Natera Inc, Other Locations
- Natera Inc, Subsidiaries
- Glossary
- Natera Inc Pipeline Products by Equipment Type
- Natera Inc Pipeline Products by Development Stage
- Natera Inc Ongoing Clinical Trials by Trial Status
